For research use only. Not for therapeutic Use.
Potent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib (Axon 1810)
| Catalog Number | I008970 |
| CAS Number | 862505-00-8 |
| Molecular Formula | C24H29FN6 |
| Purity | ≥95% |
| IUPAC Name | 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine |
| InChI | InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30) |
| SMILES | CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N |
| Reference | K Ishitsuka et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br. J. Haematol. 2008, 141(5), 598-606. |
